49,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in 6-10 Tagen
payback
25 °P sammeln
  • Broschiertes Buch

The aims of this book was to gather insights and investigate the factors influencing the response of Acute Promyelocytic Leukemia patients to conventional chemotherapy. Monitoring the response to APL therapy is a continuum that begins at diagnosis and carries on serially throughout the entire course of treatment. This is the first study from the valley of Kashmir (North India) on Acute Promyelocytic Leukemia so far in terms of following up on the disease. Our study confirmed karyotyping using peripheral blood as an analyte is a key determinant in overall disease outcome, successful remission…mehr

Produktbeschreibung
The aims of this book was to gather insights and investigate the factors influencing the response of Acute Promyelocytic Leukemia patients to conventional chemotherapy. Monitoring the response to APL therapy is a continuum that begins at diagnosis and carries on serially throughout the entire course of treatment. This is the first study from the valley of Kashmir (North India) on Acute Promyelocytic Leukemia so far in terms of following up on the disease. Our study confirmed karyotyping using peripheral blood as an analyte is a key determinant in overall disease outcome, successful remission induction, relapse risk and overall survival. We also reported promoter hypermethylation status of p15 gene as a prospective prognostic indicator and a reliable clinical aid in assessment of patients with APL. This opens up a new vista for other researchers to carry out further research into the disease in order to find out how relevant or otherwise the observations and technique would be forfuture use.
Autorenporträt
Ich Dr. Shahid M. Baba wurde in Srinagar, Kaschmir, Indien, geboren. Ich studierte in Kaschmir am führenden Tertiärkrankenhaus Sher-i-Kasmir Institute of Medical Sciences (SKIMS), Soura, wo ich drei Studiengänge erfolgreich abschloss: B.Sc. in Medizinischer Labortechnik, MSc in Immunologie & Molekularer Medizin und Ph.D in Immunologie & Molekularer Medizin im Mai 2017.